Refine by
Pain Clinic Articles & Analysis
18 news found
Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain. Multiple clinical studies have demonstrated that cebranopadol is efficacious in different types of pain. ...
(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with ...
“The groundbreaking technology behind the Evoke System’s ability to intelligently measure spinal cord activation has had many of us excited for a long time,” said Nagy Mekhail, MD, PhD, Professor at the Cleveland Clinic Lerner College of Medicine, Director of Evidence-Based Pain Medicine Research and Education in the Department of ...
The Company executed the first double-blind pivotal randomized controlled trial (RCT) in the history of spinal cord stimulation (SCS) that showed nearly 9 out 10 patients experience long-term pain relief and clinically meaningful improvements in quality of life, performing activities of daily living, sleep, mood and opioid reduction with zero explants due to loss ...
“Modulating stimulation pulse width has the potential to selectively recruit particular nerve fibers that could benefit patients with difficult to address pain patterns. With the introduction of a pulse width expanded to 2,000 microseconds, I now have one more tool to help address the short- and long-term pain relief needs of individual patients suffering ...
Oncomfort, the leader in Digital SedationTM for relieving patients’ pain and anxiety without medication, is pleased to announce the appointment of Karl Schweitzer as non-executive Director and Chairman of the Board. With this appointment, Oncomfort brings on board the experienced leadership to guide the organisation in its global expansion and significant knowledge for the ...
(NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today responded to Medtronic's announcement of FDA approval for painful diabetic neuropathy (PDN). ...
SENZA-NSRBP Randomized Controlled Trial Results Show Profound Improvements in Non-Surgical Refractory Back Pain Patients Receiving 10 kHz Therapy Relative to Conventional Medical Management at 12-Months Follow-Up. ...
The publication, titled “Neuromodulation using ultra low frequency current waveform reversibly blocks axonal conduction and chronic pain,” was a collaboration spanning three continents, and describes groundbreaking research on how ULF™ neuromodulation inhibits pain signals in pre-clinical animal models, computational models, and ...
The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. ...
Scivita Medical accurately grasps trie clinical needs, and combines Innovative technologies In multi-disciplinary fields to develop excellent Chinese products that are recognized by clinical experts worldwide.Workrs first 2D to 3D " 3D Visualization System" developed by Scivita Medical obtained NMFA certification and CE certification In Jury 2018. and became the ...
The grant will support the pre-clinical development of CFTX-1554, Confo’s lead candidate for neuropathic pain, which was initially discovered under a previous VLAIO research grant. ...
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of ...
(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the Painful Diabetic Neuropathy (PDN) and Non-Surgical ...
Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) ...
The Targets trial is set to enroll 300 subjects across 20 centers in the U.S. with the primary objective of observing DYV-700’s efficacy in reducing pain intensity and duration of pain. Dyve CEO Dr. Ryan Beal told MassDevice last week that specific marks have not yet been set, but he is looking for a 50% reduction in pain. ...
The pain became so intense, he had to give up hobbies he loved like running, hiking and karate. ...
Panag Pharma hosted a seminar for Health Care Professionals and the launch of a Regional Pilot Program to introduce Topical AOTC, a new generation pain and inflammation product. Topical AOTC is a Health Canada approved natural product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and ...